Grants>Drug Discovery/ Drug Development

Call for Nominations: Gary Neil Prize for Innovation in Drug Development

The Gary Neil Prize for Innovation in Drug Development was established in 2004 to honor the memory of Gary Neil, Ph.D. Dr. Neil, a former leader of worldwide Research and Development at Wyeth-Ayerst, was a pioneer in the field of drug development. Dr. Neil was instrumental in creating a highly effective drug development and strategic decision-making structure at Alza through his roles as CEO and President of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals Corporation. Dr. Neil had a significant role as a member of the boards of directors of Pharsight Corporation, Geron Corporation, Calydon and several other biotech companies.

The goal of the Gary Neil Prize for Innovation in Drug Development is to stimulate the application of innovative science to clinical drug development by recognizing outstanding individuals or teams who have been leaders in this area.

Eligibility

Individuals as well as teams who have demonstrated leadership in the application of significant, innovative science to clinical drug development. The award is open to individuals from all clinical pharmacology employment sectors.

Prize and Presentation

The Gary Neil Prize for Innovation in Drug Development will be presented at the ASCPT Annual Meeting. The recipient will receive a plaque and a $2,500 honorarium. Travel expenses, hotel expenses and meeting registration will be reimbursed by the Society.

The nomination deadline is Thursday, June 27, 2013.

To submit a nomination, please complete the online nomination form. Please send CVs, letters of support, and other supporting documents to ASCPT at meetings@ascpt.org

Children's Tumor Foundation Drug Discovery Initiative Award

Drug Discovery Initiative (DDI) Awards fund pilot stage drug testing offering seed grants of $25,000 for in vitro studies and $50,000 for in vivo studies.

Established in 2006, DDI Awards have been one of the Children's Tumor Foundation's most successful programs. Many DDI awardees have successfully secured follow-on funding, and established key relationships with the biotech and pharmaceutical industries.

The next DDI Award deadlines are April 15th & August 31st.

If you have any questions please contact Dan Aiese at daiese@ctf.org.

International Rett Syndrome Foundation Translational Research Program

Cycle 2 Letter of Intent due:  July 1, 2013

IRSF announces the availability of HeART (Help Accelerate RTT Therapeutics) and ANGEL (Advanced Neurotherapeutic Grant of Excellence) grant awards to promote the development and testing of therapeutics to treat and reverse Rett syndrome (RTT) and its symptoms. These award mechanisms seek to facilitate the development and testing of novel therapeutics targeting the underlying pathology of the disorder, thereby leading to an amelioration of symptoms or ultimately a pharmacological reversal of RTT. Through these awards, IRSF seeks to foster academic and public-private partnerships and further facilitate drug discovery, development and testing.

IRSF encourages novel research programs that broadly encompass the following areas of unmet need:

Design, synthesis and testing of potential disease modifying therapeutics to treat or reverse RTT

Testing of existing therapeutics both in vitro and in vivo to repurpose their use in RTT

Development and/or validation of in vitro and in vivo models of RTT for therapeutic testing

Development and/or validation of novel biomarkers for objective clinical trials outcome measures

Testing of IND-ready therapeutics in pilot clinical trials

IRSF encourages investigators to utilize the newly available IRSF SMART Library of compounds in their proposed studies.

HeART (Help Accelerate RTT Therapeutics) Grant Award

Goal: To provide seed funding for early stage drug discovery and development efforts.

Funding: The maximum funding level for HeART grant awards is $150,000 for two years.

HeART grant awards are provided for cell-based assay development, early-stage drug discovery and development, early stage medicinal chemistry efforts on high value candidate therapeutics, cell-based screening of candidate therapeutics and follow-on early-stage in vivo testing. Grant applications for exploratory studies towards development of biomarkers or objective clinical outcome measures will also be considered.

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Grant Award

Goal: To provide funding for the later stages of translational research.

Funding: The maximum funding level for ANGEL grant awards is $300,000 per year for up to two years.

Proposals must be comprised of very specific programs focused on pre-clinical drug discovery and development or clinical testing of therapeutic candidates. This mechanism requires development of a milestone based research plan, interim reporting on milestones and interaction with IRSF staff prior to and during the award period. The budget and duration of funding are variable and continued funding will be based on satisfactory progress on milestones. Applications are usually solicited, however, unsolicited proposals will be considered. Preliminary inquiries are required to determine IRSF’s level of interest prior to submission of an Expression of Interest (EOI).

Frequency:

Awards will be made in two cycles in 2013.

Please Note: IRSF requires all applicants to use our online submission process.

For application submission inquiries, please contact:

Janice Ascano, Ph.D. Manager of Grants and Research - jascano@rettsyndrome.org | 917-267-4504

For program related inquiries, please contact:

Steve Kaminsky, Ph.D., Chief Science Officer - skaminsky@rettsyndrome.org | 301-961-1559